A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients

The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information collected in routine clinical practice, prior to and independent of this study.

NCT Number	NCT07690319
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Hidradenitis Suppurativa
Enrollment	186 participants
Start Date	2026-10-15
Primary Completion	2027-03-15 (estimated)
Study Completion	2027-03-15 (estimated)
Updated on ClinicalTrials.gov	2026-07-08